Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Vaccines01:30

Cancer Vaccines

1.3K
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
1.3K
Tumor Immunotherapy01:27

Tumor Immunotherapy

2.3K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.3K
Vaccines01:21

Vaccines

51
Vaccines are among the most effective tools in preventive medicine, designed to prepare the immune system to recognize and combat infectious agents. By introducing antigens—substances that the immune system identifies as foreign—vaccines stimulate an adaptive immune response that leads to immunological memory. This immunological memory enables the body to mount a faster and more effective response upon future exposures to the actual pathogen.Vaccines can be categorized based on the...
51
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.8K
1.8K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

6.4K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

GABA promotes resistance to immunotherapy in patients with TLS-positive tumors.

Cancer cell·2026
Same authorSame journal

The peripheral immune landscape of human breast cancer.

Oncoimmunology·2026
Same author

The critical role of the endogenous immune compartment after CAR T cell therapy in recurrent GBM.

Cell·2026
Same author

Fibroblasts hold the key to TLS formation.

Immunity·2026
Same author

Pan-cancer spatial atlas of tertiary lymphoid structures.

Science (New York, N.Y.)·2026
Same author

The immunology of human breast cancer.

Nature reviews. Immunology·2026

Related Experiment Video

Updated: Apr 7, 2026

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
10:18

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

1.8K

Trial Watch: Peptide-based anticancer vaccines.

Jonathan Pol1, Norma Bloy2, Aitziber Buqué1

  • 1Gustave Roussy Cancer Campus ; Villejuif, France ; INSERM, U1138 ; Paris, France ; Equipe 11 labellisée par la Ligue Nationale contre le Cancer; Center de Recherche des Cordeliers ; Paris, France.

Oncoimmunology
|July 3, 2015
PubMed
Summary

Cancer peptide vaccines harness tumor antigens to stimulate immune responses, showing promise in therapeutic applications. Research focuses on identifying tumor rejection antigens and optimizing adjuvant strategies for enhanced efficacy.

Keywords:
APC, antigen-presenting cellCMP, carbohydrate-mimetic peptideEGFR, epidermal growth factor receptorFDA, Food and Drug AdministrationGM-CSF, granulocyte macrophage colony stimulating factorHPV, human papillomavirusIDH1, isocitrate dehydrogenase 1 (NADP+), solubleIDO1, indoleamine 2, 3-dioxygenase 1IFNα, interferon αIL-2, interleukin-2MUC1, mucin 1NSCLC, non-small cell lung carcinomaPADRE, pan-DR binding peptide epitopePPV, personalized peptide vaccinationSLP, synthetic long peptideTAA, tumor-associated antigenTERT, telomerase reverse transcriptaseTLR, Toll-like receptorTRA, tumor rejection antigenWT1carbohydrate-mimetic peptidesimmune checkpoint blockersimmunostimulatory cytokinessurvivinsynthetic long peptides

More Related Videos

Preparation, Characteristics, Toxicity, and Efficacy Evaluation of the Nasal Self-Assembled Nanoemulsion Tumor Vaccine In Vitro and In Vivo
07:33

Preparation, Characteristics, Toxicity, and Efficacy Evaluation of the Nasal Self-Assembled Nanoemulsion Tumor Vaccine In Vitro and In Vivo

Published on: September 28, 2022

2.4K
Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

10.4K

Related Experiment Videos

Last Updated: Apr 7, 2026

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
10:18

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

1.8K
Preparation, Characteristics, Toxicity, and Efficacy Evaluation of the Nasal Self-Assembled Nanoemulsion Tumor Vaccine In Vitro and In Vivo
07:33

Preparation, Characteristics, Toxicity, and Efficacy Evaluation of the Nasal Self-Assembled Nanoemulsion Tumor Vaccine In Vitro and In Vivo

Published on: September 28, 2022

2.4K
Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

10.4K

Area of Science:

  • Oncology
  • Immunology
  • Vaccine Development

Background:

  • Malignant cells express tumor-associated antigens (TAAs) that can be targeted for immune-mediated anticancer responses.
  • Peptide vaccines, using TAAs or their peptides with adjuvants, have demonstrated antineoplastic effects in preclinical models.
  • Despite limitations, cancer vaccines are actively investigated clinically, yielding promising therapeutic results.

Approach:

  • Administration of tumor-associated antigens (TAAs) or peptides as recombinant proteins with adjuvants.
  • Utilizing potent immunostimulatory regimens to enhance vaccine efficacy.
  • Focusing on identifying tumor rejection antigens for complete disease eradication.

Key Points:

  • Peptide vaccines have shown efficacy in murine tumor models.
  • Clinical investigations of cancer vaccines are ongoing with encouraging outcomes.
  • Identifying TAAs that elicit potent immune responses is crucial for therapeutic success.
  • Combinatorial strategies with superior adjuvants are being explored.

Conclusions:

  • Peptide vaccines represent a promising immunotherapeutic approach for cancer treatment.
  • Advances in identifying tumor rejection antigens and adjuvant therapies are critical for future development.
  • Continued research is essential to overcome limitations and improve the efficacy of cancer peptide vaccines.